SCHEMBL6723221

SCHEMBL6723221

Cc1cccc(-c2noc(C(F)F)c2-c2ccc(S(C)(=O)=O)c(F)c2)n1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 6/20 0.40
THRB P10828 4/20 0.40
PIK3CD O00329 2/20 0.35
PIK3CA P42336 2/20 0.35
PIK3CB P42338 2/20 0.35
PIK3CG P48736 2/20 0.35
MAPK14 Q16539 3/20 0.34
GHSR Q92847 1/20 0.34
PTGS2 P35354 2/20 0.33
GPR119 Q8TDV5 3/20 0.33
PTGS1 P23219 1/20 0.33
ELANE P08246 1/20 0.32
KDR P35968 1/20 0.32
ALDH1A1 P00352 1/20 0.32
ALOX5AP P20292 1/20 0.32
FEN1 P39748 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6722661 0.91 PTGS2 (0.43) TGFBR1THRBMAPK14GHSRPTGS2
SCHEMBL6734889 0.88 TGFBR1 (0.35) TGFBR1THRBMAPK14PTGS2KDR
SCHEMBL6726466 0.84 TGFBR1 (0.40) TGFBR1THRBPIK3CDPIK3CAPIK3CB
SCHEMBL6729041 0.84 PTGS2 (0.47) TGFBR1THRBPIK3CDPIK3CAPIK3CB
SCHEMBL6730308 0.83 PTGS2 (0.37) PIK3CDPIK3CAPIK3CBPIK3CGMAPK14
SCHEMBL6723177 0.83 PIK3CD (0.37) THRBPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL6730515 0.83 TGFBR1 (0.40) TGFBR1THRBPIK3CDPIK3CAPIK3CB
SCHEMBL6723710 0.83 PTGS2 (0.45) MAPK14PTGS2PTGS1ALDH1A1
SCHEMBL6722731 0.83 PTGS2 (0.42) PIK3CDPIK3CAPIK3CBPIK3CGMAPK14
SCHEMBL6737061 0.82 CA4 (0.39) TGFBR1THRBPTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 TGFBR1 1380/4885THRB 1783/4885PIK3CD 4290/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 TGFBR1 1568/4885THRB 1714/4885PIK3CD 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.